查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1538518

血脂异常症治疗药物市场报告：2030 年趋势、预测与竞争分析

Dyslipidaemia Drug Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

血脂异常症治疗药物的趋势与预测

预计到2030年，全球血脂异常症药物市场将达到约440亿美元，2024年至2030年的复合年增长率为9.4%。这个市场的主要驱动力是糖尿病和血脂异常症患者数量的增加、世界上老年人数量的增加以及胆固醇水平异常和脂质相关疾病发生率的增加。全球血脂异常症药物市场前景广阔，医院药局和零售药局市场充满机会。

血脂异常症治疗的分段治疗

本研究按药物类型、应用和地区预测了血脂异常症药物的全球市场。

血脂异常症药物市场洞察

Lucintel 预测，他汀类药物预计将在预测期内实现高速成长。

在这个市场中，医院药局在预测期内可能仍占较大份额。

预计北美在预测期内将经历最高的成长。

常问问题

Q1.市场规模为：

A1. 预计到 2030 年，全球血脂异常症药物市值将达到 440 亿美元。

Q2.市场成长预测是多少：

A2. 2024年至2030年，全球血脂异常症治疗药物市场预计将以9.4%的复合年增长率成长。

Q3.影响市场成长的主要驱动因素是：

A3.该市场的主要驱动力是糖尿病和血脂异常症患者数量的增加、世界上老年人数量的增加以及胆固醇水平异常和脂质相关疾病的发生频率的增加。

Q4.市场的主要细分市场是：

A4. 由于医院药局市场和零售药局市场的机会，血脂异常症药物市场的前景看好。

Q5.市场的主要企业是：

A5.血脂异常症治疗药物的主要企业如下：

  • AstraZeneca
  • Bayer
  • Amgen
  • Merck
  • Shionogi
  • Novartis
  • Pfizer
  • Bristol-Myers Squibb Company
  • Mylan
  • Abbott Laboratories

Q6.未来最大的细分市场是什么？

A6.Lucintel 预计他汀类药物在预测期内将经历高速成长。

Q7. 未来五年预计哪些地区的市场成长最大？

A7. 预计北美地区在预测期内将出现最高成长。

Q8. 可以客製化报告吗？

A8. 是的，Lucintel 提供 10% 的客製化服务，无需额外付费。

目录

第一章执行摘要

第二章 全球血脂异常症治疗药物市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球血脂异常症治疗药物市场趋势（2018-2023）与预测（2024-2030）
  • 按药物类型分類的全球血脂异常症药物市场
    • 非他汀类药物
    • 他汀类药物
  • 按应用分類的全球血脂异常症治疗市场
    • 医院药房
    • 零售药房
    • 其他的

第四章 2018-2030年区域市场趋势及预测分析

  • 按地区分類的全球血脂异常症药物市场
  • 北美血脂异常症治疗市场
  • 欧洲血脂异常症药物市场
  • 亚太地区血脂异常症异常药物市场
  • 其他地区血脂异常症治疗药物市场

第五章 竞争分析

  • 产品系列分析
  • 业务整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 全球血脂异常症药物市场按药物类型分類的成长机会
    • 按应用分類的血脂异常症治疗市场的成长机会
    • 全球血脂异常症药物市场成长机会（按地区）
  • 全球血脂异常症药物市场新趋势
  • 战略分析
    • 新产品开发
    • 扩大全球血脂异常症药物市场的容量
    • 全球血脂异常症药物市场的合併、收购与合资
    • 认证和许可

第七章主要企业概况

  • AstraZeneca
  • Bayer
  • Amgen
  • Merck
  • Shionogi
  • Novartis
  • Pfizer
  • Bristol-Myers Squibb Company
  • Mylan
  • Abbott Laboratories
简介目录

Dyslipidaemia Drug Trends and Forecast

The future of the global dyslipidaemia drug market looks promising with opportunities in the hospital pharmacy and retail pharmacy markets. The global dyslipidaemia drug market is expected to reach an estimated $44.0 billion by 2030 with a CAGR of 9.4% from 2024 to 2030. The major drivers for this market are rise in the number of diabetic and dyslipidemia patients, growing number of elderly people worldwide, and increasing frequency of abnormal cholesterol levels and lipid-associated disorders.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Dyslipidaemia Drug by Segment

The study includes a forecast for the global dyslipidaemia drug by drug type, application, and region.

Dyslipidaemia Drug Market by Drug Type [Shipment Analysis by Value from 2018 to 2030]:

  • Non-Statins Drugs
  • Statins Drugs

Dyslipidaemia Drug Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

Dyslipidaemia Drug Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Dyslipidaemia Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies dyslipidaemia drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the dyslipidaemia drug companies profiled in this report include-

  • AstraZeneca
  • Bayer
  • Amgen
  • Merck
  • Shionogi
  • Novartis
  • Pfizer
  • Bristol-Myers Squibb Company
  • Mylan
  • Abbott Laboratories

Dyslipidaemia Drug Market Insights

Lucintel forecasts that statins drug is expected to witness higher growth over the forecast period.

Within this market, hospital pharmacy will remain larger segment over the forecast period.

North America is expected to witness the highest growth over the forecast period.

Features of the Global Dyslipidaemia Drug Market

Market Size Estimates: Dyslipidaemia drug market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Dyslipidaemia drug market size by drug type, application, and region in terms of value ($B).

Regional Analysis: Dyslipidaemia drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug types, applications, and regions for the dyslipidaemia drug market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the dyslipidaemia drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the dyslipidaemia drug market size?

Answer: The global dyslipidaemia drug market is expected to reach an estimated $44.0 billion by 2030.

Q2. What is the growth forecast for dyslipidaemia drug market?

Answer: The global dyslipidaemia drug market is expected to grow with a CAGR of 9.4% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the dyslipidaemia drug market?

Answer: The major drivers for this market are rise in the number of diabetic and dyslipidemia patients, growing number of elderly people worldwide, and increasing frequency of abnormal cholesterol levels and lipid-associated disorders.

Q4. What are the major segments for dyslipidaemia drug market?

Answer: The future of the dyslipidaemia drug market looks promising with opportunities in the hospital pharmacy and retail pharmacy markets.

Q5. Who are the key dyslipidaemia drug market companies?

Answer: Some of the key dyslipidaemia drug companies are as follows:

  • AstraZeneca
  • Bayer
  • Amgen
  • Merck
  • Shionogi
  • Novartis
  • Pfizer
  • Bristol-Myers Squibb Company
  • Mylan
  • Abbott Laboratories

Q6. Which dyslipidaemia drug market segment will be the largest in future?

Answer: Lucintel forecasts that statins drug is expected to witness higher growth over the forecast period.

Q7. In dyslipidaemia drug market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness the highest growth over the forecast period.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the dyslipidaemia drug market by drug type (non-statins drugs and statins drugs), application (hospital pharmacy, retail pharmacy, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Dyslipidaemia Drug Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Dyslipidaemia Drug Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Dyslipidaemia Drug Market by Drug Type
    • 3.3.1: Non-Statins Drugs
    • 3.3.2: Statins Drugs
  • 3.4: Global Dyslipidaemia Drug Market by Application
    • 3.4.1: Hospital Pharmacy
    • 3.4.2: Retail Pharmacy
    • 3.4.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Dyslipidaemia Drug Market by Region
  • 4.2: North American Dyslipidaemia Drug Market
    • 4.2.1: North American Dyslipidaemia Drug Market by Drug Type: Non-Statins Drugs and Statins Drugs
    • 4.2.2: North American Dyslipidaemia Drug Market by Application: Hospital Pharmacy, Retail Pharmacy, and Others
  • 4.3: European Dyslipidaemia Drug Market
    • 4.3.1: European Dyslipidaemia Drug Market by Drug Type: Non-Statins Drugs and Statins Drugs
    • 4.3.2: European Dyslipidaemia Drug Market by Application: Hospital Pharmacy, Retail Pharmacy, and Others
  • 4.4: APAC Dyslipidaemia Drug Market
    • 4.4.1: APAC Dyslipidaemia Drug Market by Drug Type: Non-Statins Drugs and Statins Drugs
    • 4.4.2: APAC Dyslipidaemia Drug Market by Application: Hospital Pharmacy, Retail Pharmacy, and Others
  • 4.5: ROW Dyslipidaemia Drug Market
    • 4.5.1: ROW Dyslipidaemia Drug Market by Drug Type: Non-Statins Drugs and Statins Drugs
    • 4.5.2: ROW Dyslipidaemia Drug Market by Application: Hospital Pharmacy, Retail Pharmacy, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Dyslipidaemia Drug Market by Drug Type
    • 6.1.2: Growth Opportunities for the Global Dyslipidaemia Drug Market by Application
    • 6.1.3: Growth Opportunities for the Global Dyslipidaemia Drug Market by Region
  • 6.2: Emerging Trends in the Global Dyslipidaemia Drug Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Dyslipidaemia Drug Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Dyslipidaemia Drug Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: AstraZeneca
  • 7.2: Bayer
  • 7.3: Amgen
  • 7.4: Merck
  • 7.5: Shionogi
  • 7.6: Novartis
  • 7.7: Pfizer
  • 7.8: Bristol-Myers Squibb Company
  • 7.9: Mylan
  • 7.10: Abbott Laboratories